Atlas Trials

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

Clinical trial NCT04856930 · COMPLETED

Trial details

NCT number
NCT04856930
Sponsor
Vanda Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hidradenitis Suppurativa
Start date
2021-07-07
Primary completion
2022-07-15
Enrollment
149

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.